Literature DB >> 15317708

Degree, duration, and causes of visual loss in uveitis.

O M Durrani1, N N Tehrani, J E Marr, P Moradi, P Stavrou, P I Murray.   

Abstract

BACKGROUND/AIMS: Uveitis is a major cause of visual morbidity in the working age group. The authors investigated the duration, degree, and causes of visual loss in uveitis patients with the aim of better defining the visual morbidity and identifying potential risk factors.
METHODS: A retrospective, non-interventional, observational survey of 315 consecutive patients attending a tertiary referral uveitis service.
RESULTS: The mean duration of follow up was 36.7 months. Reduced vision (< or =6/18) was found in 220/315 (69.95%) of the patients with a subset of 120 patients having vision < or =6/60. Unilateral visual loss occurred in 109 (49.54%), while 111 (50.45%) had bilateral loss. The mean duration of visual loss was 21 months. Of the 148 patients with pan-uveitis, 125 (84.45%) had reduced vision, with 66 (53%) having vision < or =6/60. Main causes of visual loss were cystoid macular oedema (CMO) (59/220, 26.8%), cataract (39/220, 17.7%), and combination of CMO and cataract (44/220, 20%). The following were predictive of a poorer visual prognosis: pan-uveitis (p = 0.0005), bilateral inflammation (p = 0.0005), increasing duration of reduced vision (p = 0.0005), an Indian or Pakistani ethnic background (p = 0.004), and increasing patient age (p = 0.02).
CONCLUSION: Prolonged visual loss occurred in two thirds of uveitis patients, with 70 (22%) patients meeting the criteria for legal blindness at some point in their follow up. Older patients with bilateral inflammation and an increasing duration of reduced vision are at the greatest risk of severe visual loss (< or =6/60). CMO and cataract were responsible for visual loss in 64.5% of patients.

Entities:  

Mesh:

Year:  2004        PMID: 15317708      PMCID: PMC1772296          DOI: 10.1136/bjo.2003.037226

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  33 in total

1.  Population based assessment of uveitis in an urban population in southern India.

Authors:  L Dandona; R Dandona; R K John; C A McCarty; G N Rao
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

2.  Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center.

Authors:  B Bodaghi; N Cassoux; B Wechsler; D Hannouche; C Fardeau; T Papo; D L Huong; J C Piette; P LeHoang
Journal:  Medicine (Baltimore)       Date:  2001-07       Impact factor: 1.889

Review 3.  Vogt-Koyanagi-Harada disease.

Authors:  Russell W Read
Journal:  Ophthalmol Clin North Am       Date:  2002-09

Review 4.  The natural history of uveitis.

Authors:  R B Nussenblatt
Journal:  Int Ophthalmol       Date:  1990-10       Impact factor: 2.031

Review 5.  The possible impact of uveitis in blindness: a literature survey.

Authors:  M S Suttorp-Schulten; A Rothova
Journal:  Br J Ophthalmol       Date:  1996-09       Impact factor: 4.638

6.  Uveitis and blindness.

Authors:  R S Rosner
Journal:  Med Trial Tech Q       Date:  1967-12

7.  Evaluation of foldable intraocular lenses in patients with uveitis.

Authors:  S Rauz; P Stavrou; P I Murray
Journal:  Ophthalmology       Date:  2000-05       Impact factor: 12.079

8.  Uveitis in the southeastern United States.

Authors:  P T Merrill; J Kim; T A Cox; C C Betor; R M McCallum; G J Jaffe
Journal:  Curr Eye Res       Date:  1997-09       Impact factor: 2.424

9.  How does visual impairment affect performance on tasks of everyday life? The SEE Project. Salisbury Eye Evaluation.

Authors:  Sheila K West; Gary S Rubin; Aimee T Broman; Beatriz Muñoz; Karen Bandeen-Roche; Kathleen Turano
Journal:  Arch Ophthalmol       Date:  2002-06

10.  Correlation between visual function and visual ability in patients with uveitis.

Authors:  A M Gardiner; R A Armstrong; M C M Dunne; P I Murray
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

View more
  118 in total

Review 1.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

2.  Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human lens epithelial cells: apoptosis through the formation of 3-hydroxykynurenine.

Authors:  Maneesh Mailankot; Ram H Nagaraj
Journal:  Int J Biochem Cell Biol       Date:  2010-05-06       Impact factor: 5.085

3.  [Cystoid macular edema in uveitis].

Authors:  S R Thurau
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

4.  Automated three-dimensional cell counting method for grading uveitis of rodent eye in vivo with optical coherence tomography.

Authors:  Woo J Choi; Kathryn L Pepple; Ruikang K Wang
Journal:  J Biophotonics       Date:  2018-06-11       Impact factor: 3.207

5.  Treatment of uveitis: beyond steroids.

Authors:  Virender S Sangwan
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

6.  Long-term prognosis for glaucoma in patients with Posner-Schlossman syndrome.

Authors:  Jin-Ho Kim; Ji-Young Lee; Jin A Choi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-07-23       Impact factor: 3.117

7.  Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial Cells: Potential Targets for New Biologic Drugs.

Authors:  Justine R Smith; Larry L David; Binoy Appukuttan; Phillip A Wilmarth
Journal:  Am J Ophthalmol       Date:  2018-03-17       Impact factor: 5.258

8.  Incidence and changing patterns of uveitis in Central Tokyo.

Authors:  Takafumi Suzuki; Toshikatsu Kaburaki; Rie Tanaka; Shintaro Shirahama; Keiko Komae; Hisae Nakahara; Mitsuko Takamoto; Hidetoshi Kawashima; Makoto Aihara
Journal:  Int Ophthalmol       Date:  2021-05-28       Impact factor: 2.031

9.  Cyclosporin-A associated malignancy.

Authors:  Jonathan M Durnian; Rosalind M K Stewart; Richard Tatham; Mark Batterbury; Stephen B Kaye
Journal:  Clin Ophthalmol       Date:  2007-12

10.  OUTCOMES OF PARS PLANA VITRECTOMY FOR MACULAR HOLE IN PATIENTS WITH UVEITIS.

Authors:  Natalia F Callaway; Marco A Gonzalez; Yoshihiro Yonekawa; Lisa J Faia; Efrem D Mandelcorn; Rahul N Khurana; Mohamed G A Saleh; Phoebe Lin; Lucia Sobrin; Thomas A Albini
Journal:  Retina       Date:  2018-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.